These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36438253)

  • 1. Association of visit-to-visit HbA1c variability with cardiovascular diseases in type 2 diabetes within or outside the target range of HbA1c.
    Sun B; Gao Y; He F; Liu Z; Zhou J; Wang X; Zhang W
    Front Public Health; 2022; 10():1052485. PubMed ID: 36438253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes.
    Sun B; He F; Gao Y; Zhou J; Sun L; Liu R; Xu H; Chen X; Zhou H; Liu Z; Zhang W
    Endocrine; 2019 Jun; 64(3):536-543. PubMed ID: 30868413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visit-to-Visit HbA
    Li S; Nemeth I; Donnelly L; Hapca S; Zhou K; Pearson ER
    Diabetes Care; 2020 Feb; 43(2):426-432. PubMed ID: 31727686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between visit-to-visit HbA1c variability and the risk of cardiovascular disease in patients with type 2 diabetes.
    Shen Y; Zhou J; Shi L; Nauman E; Katzmarzyk PT; Price-Haywood EG; Horswell R; Bazzano AN; Nigam S; Hu G
    Diabetes Obes Metab; 2021 Jan; 23(1):125-135. PubMed ID: 32965068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
    Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with type 2 diabetes: A subanalysis of the EMPATHY trial.
    Sato M; Inaishi J; Saisho Y; Sato Y; Komuro I; Itoh H
    J Diabetes Investig; 2021 Dec; 12(12):2190-2196. PubMed ID: 34013644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intensive glycemic control on microvascular outcomes in type 2 diabetes mellitus are modified by long-term HbA
    Wang JM; Miao MY; Jia YP; Wang XW; Wu XB; Wan ZX; Zheng Y; Qin LQ; Li FR; Chen GC
    Diabetes Res Clin Pract; 2024 Feb; 208():111100. PubMed ID: 38246509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.
    Penno G; Solini A; Zoppini G; Orsi E; Fondelli C; Zerbini G; Morano S; Cavalot F; Lamacchia O; Trevisan R; Vedovato M; Pugliese G;
    Cardiovasc Diabetol; 2013 Jul; 12():98. PubMed ID: 23829205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study.
    Sun B; He F; Sun L; Zhou J; Shen J; Xu J; Wu B; Liu R; Wang X; Xu H; Chen X; Zhou H; Liu Z; Zhang W
    Endocrine; 2019 Jan; 63(1):44-51. PubMed ID: 30121774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
    Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
    Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visit-to-visit glycemic variability is a strong predictor of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus: Competing risk analysis using a national cohort from the Taiwan diabetes study.
    Chiu HT; Li TC; Li CI; Liu CS; Lin WY; Lin CC
    PLoS One; 2017; 12(5):e0177184. PubMed ID: 28489885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visit-to-Visit Variability of Hemoglobin A
    Ghouse J; Skov MW; Kanters JK; Lind B; Isaksen JL; Blanche P; Haunsø S; Køber L; Svendsen JH; Olesen MS; Holst AG; Gerds TA; Nielsen JB
    Diabetes Care; 2019 Jan; 42(1):134-141. PubMed ID: 30352898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Long-term HbA
    Sheng CS; Tian J; Miao Y; Cheng Y; Yang Y; Reaven PD; Bloomgarden ZT; Ning G
    Diabetes Care; 2020 Jun; 43(6):1185-1190. PubMed ID: 32229597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type 2 diabetes mellitus: A post-hoc analysis of a prospective and multicenter study.
    Manosroi W; Phimphilai M; Waisayanand N; Buranapin S; Deerochanawong C; Gunaparn S; Phrommintikul A; Wongcharoen W;
    J Diabetes Investig; 2023 Dec; 14(12):1391-1400. PubMed ID: 37610280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Risk of Cardiovascular Disease Among Type 2 Diabetes Patients According to Average and Visit-to-Visit Variations of HbA1c Levels During the First 3 Years of Diabetes Diagnosis.
    Kim H; Jung DY; Lee SH; Cho JH; Yim HW; Kim HS
    J Korean Med Sci; 2023 Jan; 38(4):e24. PubMed ID: 36718561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.
    Yang CY; Su PF; Hung JY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jul; 19(1):105. PubMed ID: 32631323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.
    Bots SH; van der Graaf Y; Nathoe HM; de Borst GJ; Kappelle JL; Visseren FL; Westerink J;
    Cardiovasc Diabetol; 2016 Jul; 15(1):101. PubMed ID: 27431507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of variability in hemoglobin A1c with cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus - A retrospective population-based cohort study.
    Wan EY; Fung CS; Fong DY; Lam CL
    J Diabetes Complications; 2016; 30(7):1240-7. PubMed ID: 27318537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visit-to-visit HbA
    Yang CD; Shen Y; Lu L; Yang ZK; Hu J; Zhang RY; Shen WF; Ding FH; Wang XQ
    Cardiovasc Diabetol; 2020 Sep; 19(1):133. PubMed ID: 32887588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.